表紙
市場調査レポート

アジア太平洋地域の核医学/放射性医薬品・安定同位体市場予測

Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017

発行 MarketsandMarkets 商品コード 273261
出版日 ページ情報 英文 313 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
アジア太平洋地域の核医学/放射性医薬品・安定同位体市場予測 Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017
出版日: 2013年05月31日 ページ情報: 英文 313 Pages
概要

アジア太平洋地域の放射性医薬品市場額は、2012年に約5億米ドルとなりました。今後はCAGR10.5%で拡大し、2017年には8億2,490万米ドルに達する見込みです。同市場は大きく2つのセグメント−診断と治療−に分類され、診断セグメントは2012年におけるシェアの80.7%を構成しました。診断市場における放射性同位体(ラジオアイソトープ)はSPECTとPETに分類されます。SPECTは主に心臓病関連の診断に用いられ、2012年から2017年にかけてCAGR10.2%で拡大する構えを見せています。

当レポートでは、アジア太平洋地域の核医学/放射性医薬品および安定同位体市場について調査分析し、同位元素・アプリケーション・国別の分析、競合情勢および主要企業のプロファイルなどをまとめ、概略以下の構成でお届けします。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • イントロダクション
  • 放射性医薬品の定義
  • 市場セグメント
  • 市場力学
  • 成功の必要条件
  • 緊急の問題
  • OPAL(オーストラリアの研究用原子炉):世界的な危機に瀕する放射性同位元素「Mo-99(モリブデン99)」供給にとっての持続可能なソリューション
  • 規制問題
  • 市場シェア分析

第4章 アジア太平洋地域の放射性医薬品市場:同位元素(アイソトープ)別

  • イントロダクション
  • 診断市場
    • 機会の土台
    • 単一光子放射断層撮影法(SPECT)放射線医薬品
      • テクネチウム-99m(Tc-99m)
      • タリウム-201(TL-201)
      • ガリウム-67(GA-67)
      • ヨウ素(I-123)
      • その他
    • ポジトロン断層法(PET)放射線医薬品
      • フッ素-18
  • 治療用同位体
    • 機会の土台
    • ベータ放射体
      • ヨウ素-131(I-131)
      • イットリウム-90(Y-90)
      • サマリウム-153(Sm-153)
      • レニウム-186(Re-186)
      • ルテチウム-177(LU-177)
      • その他
    • アルファ放射体
      • ラジウム-223(RA-223)&塩化ラジウム
      • アクチニウム-225(AC-225)-212(BI-212)
      • 鉛-212(PB-212)/ビスマス
      • アスタチン-211(AT-211)
    • 小線源(近接照射)療法
      • セシウム-131
      • ヨウ素-125
      • パラジウム-103
      • イリジウム-192
      • その他

第5章 アジア太平洋地域の放射性医薬品市場:アプリケーション/適応症別

  • イントロダクション
  • 診断アプリケーション
    • SPECT
      • 心臓病
      • リンパ腫
      • 甲状腺
      • 神経学
      • その他
    • PET
      • 心臓病
      • 神経学
      • その他
  • 治療アプリケーション
    • 甲状腺
    • 骨転移
    • リンパ腫
    • 内分泌腫瘍
    • その他

第6章 アジア太平洋地域の濃縮安定同位体市場

  • イントロダクション
  • 市場概要
  • 市場力学
  • 濃縮安定市場:同位体別
    • ジュウテリウム & O-18は有望な同位体
    • 炭素13
    • ジュウテリウム
    • 酸素18
    • ニトロゲン15
    • その他の安定同位体
  • 濃縮安定市場:アプリケーション別
    • 診断&治療
    • 研究
    • 医薬品
    • 産業市場

第7章 地域分析

  • イントロダクション
  • 日本
  • 中国
  • インド
  • 韓国
  • マレーシア
  • インドネシア
  • オーストラリア
  • ニュージーランド
  • その他

第8章 競合情勢

  • イントロダクション
  • 提携、合意、コラボレーション&ジョイントベンチャー
  • 製品発売
  • 拡大
  • M&A
  • その他の発展

第9章 企業プロファイル(概要、財務、製品&サービス、戦略および開発)

図表リスト

目次
Product Code: PH 2004

The radiopharmaceuticals market in the Asia-Pacific region was valued at $500.8 million in 2012; it is poised to reach $824.9million in 2017 at a CAGR of 10.5%.

The market is broadly classified into two segments, namely, diagnostic and therapeutic; the former dominated with about 80.7% share in 2012. Radioisotopes in the diagnostic market are categorized as SPECT and PET. Technetium 99m (Tc-99m) dominated the SPECT radioisotope market in 2012, followed by thallium-201(Tl-201), gallium-67 (Ga-67), and iodine-123 (I-123). SPECT is majorly used in cardiology-related diagnosis; it is poised to grow at a CAGR of 10.2% from 2012 to 2017. The PET radioisotopes market is dominated by fluoride-18 (F-18), followed by rubidium-82 (Rb-82).

Segments in the therapeutic market are beta emitters, brachytherapy isotopes, and alpha emitters. Quantitative information about alpha emitters has not been arrived at, as they have not been commercialized; recent clinical studies have, however, showcased immense potential of alpha isotopes in therapies. Beta emitters contribute the highest to the therapy market, dominated by iodine-131(I-131), which is poised to grow at a CAGR of 7.7% from 2012 to 2017. The Asia-Pacific market is driven by its applications for thyroid cancer, hyperthyroidism, and non-Hodgkin's lymphoma. Significant isotopes in the brachytherapy market are cesium-131(Cs-131), iodine-125 (I-125), palladium-103 (Pd-103), and iridium-192 (Ir-192).

Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are boosting the growth of the Asia-Pacific nuclear medicine market. Upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The nuclear disaster at Fukushima nuclear plants in 2011 had a major impact on radioisotope production in Japan, which is the largest consumer market in the Asia-Pacific region. The Asia-Pacific region is insulated from the global crisis in Mo-99 supply since the production is based on local nuclear plants and OPAL reactor of ANSTO. ANSTO is deemed as the future solution to compensate global Mo-99 demand.

Major players in the radiopharmaceuticals market are Nihon Medi-Physics Co., Ltd. (Japan), Covidien PLC (U.S.), Fujifilm Corporation (Japan), ANSTO (Australia), and IBA S.A (Belgium).

The Asia-Pacific stable isotopes market is dominated by deuterium (D2), oxygen-18 (O-18), carbon-13 (C-13), and nitrogen-15 (N-15). Research, pharmaceuticals, diagnostic and therapy, and industries are major applications. The Asia-Pacific stable isotopes market was estimated at $56.1 million in 2012 and is expected to cross $100.0 million by 2017 at a CAGR of 12.6%.

The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) (U.S.) and Sigma Aldrich (U.S.) in 2012.

Scope of the Report

The radioisotope and stable isotope markets have been segmented according to the type of isotope, and applications. Both these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by country (Japan, China, India, South Korea, Malaysia, Indonesia, Australia, New Zealand, and Rest of Asia) to provide in-depth information on the Asia-Pacific scenario.

Asia-Pacific Radiopharmaceuticals Market

  • Diagnostic
    • SPECT
      • Tc-99m
      • Tl-201
      • Ga-67
      • I-123
      • Others
    • PET
      • F-18
      • Rb-82
      • Others
  • Therapy
    • Beta emitters
      • I-131
      • Sm-153
      • Re-186
      • Y-90
      • Lu-177
      • Others
    • Alpha emitters
    • Brachytherapy
      • Cs-131
      • I-125
      • Pd-103
      • Ir-192
      • Others

Asia-Pacific Enriched Stable Isotopes Market

  • Deuterium
  • Oxygen-18
  • Carbon-13
  • Nitrogen-15
  • Others

Radiopharmaceutical and Stable Isotope Markets, By Country

  • Japan
  • China
  • India
  • South Korea
  • Malaysia
  • Indonesia
  • Australia
  • New Zealand
  • Rest of Asia

Table of Contents

1. Introduction

  • 1.1. Key Take-Aways
  • 1.2. Report Description
  • 1.3. Markets Covered
  • 1.4. Stakeholders
  • 1.5. Research Methodology
    • 1.5.1. Market Size
    • 1.5.2. Market Share
    • 1.5.3. Key Data Points From Secondary Sources
    • 1.5.4. Key Data Points From Primary Sources
    • 1.5.5. Assumptions

2. Executive Summary

3. Market Overview

  • 3.1. Introduction
  • 3.2. Definition Of Radiopharmaceuticals
  • 3.3. Market Segmentation
    • 3.3.1. Radiopharmaceuticals
    • 3.3.2. Stable Isotopes
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increasing Incidence Of Cancer And Cardiac Ailments Boosts The Demand For Radiopharmaceuticals
      • 3.4.1.2. Increasing Use Of Spect And Pet Scans Results In Rise Of Radiopharmaceutical Usage
      • 3.4.1.3. Rising Awareness Of Radiopharmaceuticals To Spur Growth
      • 3.4.1.4. Ready Availability Of Radiopharmaceuticals From Cyclotrons To Goad The Growth
    • 3.4.2. Restraints
      • 3.4.2.1. Shorter Half-Life Of Radiopharmaceuticals Restricts The Usage
      • 3.4.2.2. High Capital To Limit The Buying Of Scanners
      • 3.4.2.3. Competition From Conventional Diagnostic Procedures
    • 3.4.3. Opportunities
      • 3.4.3.1. Potential Radioisotopes In The Pipeline
      • 3.4.3.2. Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
      • 3.4.3.3. Cyclotron-Based Production
      • 3.4.3.4. Neurological Applications
    • 3.4.4. Threat
      • 3.4.4.1. Japanese Reactors Inefficient To Compensate The Domestic Nuclear Demand
  • 3.5. Winning Imperatives
    • 3.5.1. Investments On New Radioisotopes And Novel Applications
    • 3.5.2. Shift Towards Leu-Based Mo-99 Production
  • 3.6. Burning Issues
    • 3.6.1. High Cost Of Pet Cameras
    • 3.6.2. Fukushima Nuclear Disaster
  • 3.7. Opal - A Sustainable Solution For Global Crisis In Mo-99 Supply
  • 3.8. Regulatory Affairs
    • 3.8.1. Japan
      • 3.8.1.1. The Pharmaceuticals And Medical Devices Agency (PMDA, Sogo-Kiko)
    • 3.8.2. China
      • 3.8.2.1. China Food And Drug Administration (CFDA) & Office Of Administrative Protection For Pharmaceuticals(OOAP)
    • 3.8.3. India
      • 3.8.3.1. Board Of Radiation & Isotope Technology (BRIT)
    • 3.8.4. South Korea
      • 3.8.4.1. Korea Institute Of Nuclear Safety (KINS) And Korea Institute Of Nuclear Nonproliferation And Control(KINAC)
    • 3.8.5. Malaysia
      • 3.8.5.1. Atomic Energy Licensing Board (AELB)
    • 3.8.6. Indonesia
      • 3.8.6.1. Nuclear Energy Regulatory Agency (BAPETEN)
    • 3.8.7. Australia & New Zealand
      • 3.8.7.1. The Australian And New Zealand Society Of Nuclear Medicine (ANZSNM)
    • 3.8.8. Roa
      • 3.8.8.1. Dost (Philippines) & Crpns (Singapore)
  • 3.9. Market Share Analysis
    • 3.9.1. Radiopharmaceuticals Market
    • 3.9.2. Enriched Stable Isotope Market

4. Asia-Pacific Radiopharmaceuticals Market, By Isotope

  • 4.1. Introduction
  • 4.2. Diagnostic Market
    • 4.2.1. Opportunity Matrix
    • 4.2.2. Single-Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
      • 4.2.2.1. Technetium-99m (Tc-99m)
        • 4.2.2.1.1. Tc-99m To Decide Growth Trend Of Spect Radioisotopes
        • 4.2.2.1.2. Factors Affecting Technetium-99m Market
          • 4.2.2.1.2.1. Technetium Can Combine With 31 Different Carrier Molecules
          • 4.2.2.1.2.2. Sustainable Supply Of Technetium
      • 4.2.2.2. Thallium-201 (TL-201)
        • 4.2.2.2.1. Tl-201 Is A Potential Substitute For Tc-99m
      • 4.2.2.3. Gallium-67 (GA-67)
        • 4.2.2.3.1. Fluorine-18 (PET) Might Seize Ga-67 (SPECT) Market Share In The Near Future
      • 4.2.2.4. Iodine (I-123)
      • 4.2.2.5. Others
    • 4.2.3. Positron-Emission Tomography (PET) Radiopharmaceuticals
      • 4.2.3.1. Fluorine-18
        • 4.2.3.1.1. Fdg
        • 4.2.3.1.2. Florbetapir
        • 4.2.3.1.3. Factors Affecting Fluorine-18 Market
          • 4.2.3.1.3.1. Rise In Pet Procedures Increases Demand For Fdg
          • 4.2.3.1.3.2. High Generation Costs Of Fdg
          • 4.2.3.1.3.3. Need For Speedy & Efficient Transportation
        • 4.2.3.2. Rubidium-82 (RB-82)
        • 4.2.3.3. Others
  • 4.3. Therapeutic Isotopes
    • 4.3.1. Opportunity Matrix
    • 4.3.2. Beta Emitters
      • 4.3.2.1. Iodine-131 (I-131)
      • 4.3.2.2. Yttrium-90 (Y-90)
        • 4.3.2.2.1. Y-90 Market Influenced By Popularity Of Nordion's Therasphere
      • 4.3.2.3. Samarium-153 (Sm-153)
      • 4.3.2.4. Rhenium-186 (Re-186)
      • 4.3.2.5. Lutetium-177 (LU-177)
        • 4.3.2.5.1. LU-177 Is A Potential Treatment Option For Neuroendocrine Cancer
      • 4.3.2.6. Others
        • 4.3.2.6.1. RE-188 And P-33 Are Notable Promising Isotope
    • 4.3.3. Alpha Emitters
      • 4.3.3.1. Radium-223 (RA-223) & Alpharadin
        • 4.3.3.1.1. Successful Completion Of Phase Iii Trials In Men With Bone Metastases From CRPC
        • 4.3.3.1.2. First In-Class Alpha Pharmaceutical
        • 4.3.3.1.3. Alpharadin Is Advantageous Over Taxotere, Beta-Therapy And Brachytherapy
        • 4.3.3.1.4. Success Of Alpharadin
        • 4.3.3.1.5. Porter's Five Forces Analysis
        • 4.3.3.1.6. Swot Analysis
      • 4.3.3.2. Actinium-225 (AC-225)
      • 4.3.3.3. Lead-212 (PB-212)/Bismuth-212 (BI-212)
      • 4.3.3.4. Astatine-211 (AT-211)
        • 4.3.3.5. Radium-224 (RA-224)
        • 4.3.3.6. Thorium-227 (TH-227)
    • 4.3.4. Brachytherapy
      • 4.3.4.1. Cesium-131
      • 4.3.4.2. Iodine-125
      • 4.3.4.3. Palladium-103
      • 4.3.4.4. Iridium-192
      • 4.3.4.5. Others

5. Asia-Pacific Radiopharmaceuticals Market, By Application/Indication

  • 5.1. Introduction
  • 5.2. Diagnostic Application
    • 5.2.1. Spect
      • 5.2.1.1. Cardiology
      • 5.2.1.2. Lymphoma
      • 5.2.1.3. Thyroid
      • 5.2.1.4. Neurology
        • 5.2.1.4.1. Alzheimer's, Dementia, And Parkinson's Disease Driving Growth Of The Neurology Spect Market
      • 5.2.1.5. Others
    • 5.2.2. Pet
      • 5.2.2.1. Oncology
        • 5.2.2.1.1. Fdg F-18 Has Become A Gold Standard For Oncology Diagnosis Using Pet Scan
      • 5.2.2.2. Cardiology
      • 5.2.2.3. Neurology
      • 5.2.2.4. Others
  • 5.3. Therapeutic Application
    • 5.3.1. Thyroid
    • 5.3.2. Bone Metastasis
    • 5.3.3. Lymphoma
    • 5.3.4. Endocrine Tumors
    • 5.3.5. Others

6. Asia-Pacific Enriched Stable Isotopes Market

  • 6.1. Introduction
  • 6.2. Market Overview
  • 6.3. Market Dynamics
    • 6.3.1. Drivers
      • 6.3.1.1. Stable Isotopes Are Natural In Origin & Hence Safe
      • 6.3.1.2. Proteomics & System Biology, Major Factors To Boost The Growth Of Stables
      • 6.3.1.3. Medical Applications Propel Stable Isotopes Market Growth
    • 6.3.2. Restraints
      • 6.3.2.1. Harmful Effects Of High Doses Of Stable Isotopes Affect Market Growth
      • 6.3.2.2. High Cost Of Stables Isotope
  • 6.4. Enriched Stables Market, By Isotope
    • 6.4.1. Deuterium & O-18 Are Promising Isotopes
    • 6.4.2. Carbon-13
    • 6.4.3. Deuterium
    • 6.4.4. Oxygen-18
    • 6.4.5. Nitrogen-15
    • 6.4.6. Other Stable Isotopes
  • 6.5. Enriched Stables Market, By Application
    • 6.5.1. Diagnostic & Therapy
    • 6.5.2. Research
    • 6.5.3. Pharmaceutical
    • 6.5.4. Industrial Sector

7. Geographic Analysis

  • 7.1. Introduction
    • 7.1.1. Apac Showcases Great Scope For Market Development
  • 7.2. Japan
    • 7.2.1. Pet Diagnosis Increased Dramatically After 2002
    • 7.2.2. Japanese Nuclear Market Affected By Fukushima Catastrophe In 2011
  • 7.3. China
    • 7.3.1. Alternative Procedures Hinder Nuclear Medicine Market
  • 7.4. India
    • 7.4.1. Tc-99m And F-18 Fdg, The Most Prominent Radiopharmaceuticals
  • 7.5. South Korea
    • 7.5.1. Nuclear Medicines Market Gained Momentum After Mid-1990s
  • 7.6. Malaysia
    • 7.6.1. Nuclear Medicines Market Showcased A Significant Development During The Post 1970's Era
    • 7.6.2. Patients Migrating To Neighboring Countries For Nuclear Medicine Services
  • 7.7. Indonesia
    • 7.7.1. Lack Of Skilled Professionals Affects Indonesian Nuclear Medicines Market
  • 7.8. Australia
    • 7.8.1. The Opal Reactor Has The Capacity To Produce Almost Half The Global Tc-99m Demand
    • 7.8.2. Uninterrupted Mo-99 Production By Opal To Boost Tc-99m Usage
  • 7.9. New Zealand
    • 7.9.1. Alternative Procedures Affect Nuclear Medicines Market
  • 7.10. Rest Of Asia (Roa)

8. Competitive Landscape

  • 8.1. Introduction
  • 8.2. Agreements, Partnerships, Collaborations & Joint Ventures
  • 8.3. Products Launch
  • 8.4. Expansions
  • 8.5. Mergers & Acquisitions
  • 8.6. Other Developments

9. Company Profiles (Overview, Financials, Products & Services, Strategy, & Developments)*

  • 9.1. Bracco Imaging S.P.A.
  • 9.2. Cambridge Isotope Laboratories, Inc.
  • 9.3. Cardinal Health, Inc.
  • 9.4. Covidien, Plc
  • 9.5. Eczacibasi-Monrol
  • 9.6. Fujifilm Holdings Corporation
  • 9.7. Ge Healthcare (Subsidiary Of General Electric Company)
  • 9.8. Iba Group
  • 9.9. Isotec, Inc. (Sigma-Aldrich)
  • 9.10. Lantheus Medical Imaging, Inc.
  • 9.11. Nordion, Inc.
  • 9.12. Ntp Radioisotopes (Pty), Ltd.
  • 9.13. Siemens Healthcare (Subsidiary Of Siemens AG)
  • 9.14. Taiyo Nippon Sanso Corporation
  • 9.15. Urenco Limited
  • 9.16. Rotem Industries, Ltd., Inc.
  • 9.17. Australian Nuclear Association And Technology Organization (ANSTO)
  • 9.18. Board Of Radiation And Isotope Technology (BRIT)
  • 9.19. Institute Of Atomic Energy Polatom Radioisotope Centre
  • 9.20. Institute Of Isotopes Co., Ltd.
  • 9.21. Institute Of Radioelement (IRE)

List Of Tables

  • Table 1: Asia-Pacific: Radiopharmaceutical Diagnostic Market,By Technology, 2010 - 2017 ($Million)
  • Table 2: Asia-Pacific: Radiopharmaceutical Diagnostic Market, By Technology, 2010 - 2017 ($Million)
  • Table 3: Asia-Pacific: Spect Radiopharmaceuticals Market, By Isotope, 2010 - 2017 ($Million)
  • Table 4: Asia-Pacific: Spect Radiopharmaceuticals Market, By Country, 2010 - 2017 ($Million)
  • Table 5: Indications Diagnosed By Tc-99m
  • Table 6: Asia-Pacific: Tc-99m Market, By Country, 2010 - 2017 ($Million)
  • Table 7: Asia-Pacific: Tl-201 Market, By Country, 2010 - 2017 ($Million)
  • Table 8: Asia-Pacific: Ga-67 Market, By Country, 2010 - 2017 ($Million)
  • Table 9: Asia-Pacific: I-123 Market, By Country, 2010 - 2017 ($Million)
  • Table 10: Asia-Pacific: Other Radiopharmaceuticals Market, By Country, 2010 - 2017 ($Million)
  • Table 11: Asia-Pacific: Pet Radiopharmaceuticals Market, By Isotope, 2010 - 2017 ($Million)
  • Table 12: Asia-Pacific: Pet Radiopharmaceuticals Market, By Country, 2010 - 2017 ($Million)
  • Table 13: Asia-Pacific: F-18 Market, By Country, 2010 - 2017 ($Million)
  • Table 14: Asia-Pacific: Rb-82 Market, By Country, 2010 - 2017 ($Million)
  • Table 15: Asia-Pacific: Other Pet Radiopharmaceuticals Market, By Country, 2010 - 2017 ($Million)
  • Table 16: Asia-Pacific: Radiopharmaceutical Market, By Therapy, 2010 - 2017 ($Million) 86
  • Table 17: Asia-Pacific: Beta Emitter Radiopharmaceuticals Market, By Isotope, 2010 - 2017 ($Million)
  • Table 18: Asia-Pacific: Beta Emitter Radiopharmaceuticals Market, By Country, 2010 - 2017 ($Million)
  • Table 19: Asia-Pacific: I-131 Market, By Country, 2010 - 2017 ($Million)
  • Table 20: Asia-Pacific: Y-90 Market, By Country, 2010 - 2017 ($Million)
  • Table 21: Asia-Pacific: Sm-153 Market, By Country, 2010 - 2017 ($Million)
  • Table 22: Asia-Pacific: Re-186 Market, By Country, 2010 - 2017 ($Million)
  • Table 23: Asia-Pacific: Lu-177 Market, By Country, 2010 - 2017 ($Million)
  • Table 24: Asia-Pacific: Other Beta Emitters Market, By Country, 2010 - 2017 ($Million)
  • Table 25: Alpha Emitters Vs Beta Emitters
  • Table 26: Radiopharmaceuticals Characteristics & Dose Delivery Over Time
  • Table 27: Asia-Pacific: Brachytherapy Market, By Isotope, 2010 - 2017 ($Million)
  • Table 28: Asia-Pacific: Brachytherapy Market, By Country, 2010 - 2017 ($Million)
  • Table 29: Asia-Pacific: Cs-131 Market, By Country, 2010 - 2017 ($Million)
  • Table 30: Asia-Pacific: I-125 Market, By Country, 2010 - 2017 ($Million)
  • Table 31: Asia-Pacific: Pd-103 Market, By Country, 2010 - 2017 ($Million)
  • Table 32: Asia-Pacific: Ir-192 Market, By Country, 2010 - 2017 ($Million)
  • Table 33: Asia-Pacific: Other Brachytherapy Market, By Country, 2010 - 2017 ($Million)
  • Table 34: Asia-Pacific: Spect Application Market, 2010 - 2017 ($Million)
  • Table 35: Asia-Pacific: Cardiology Spect Market, By Country, 2010 - 2017 ($Million)
  • Table 36: Asia-Pacific: Lymphoma Spect Market, By Country, 2010 - 2017 ($Million)
  • Table 37: Asia-Pacific: Thyroid Spect Market, By Country, 2010 - 2017 ($Million)
  • Table 38: Asia-Pacific: Neurology Spect Market, By Country, 2010 - 2017 ($Million)
  • Table 39: Asia-Pacific: Other Spect Applications Market, By Country, 2010 - 2017 ($Million)
  • Table 40: Asia-Pacific: Pet Application Market, 2010 - 2017 ($Million)
  • Table 41: Asia-Pacific: Oncology Pet Market, By Country, 2010 - 2017 ($Million)
  • Table 42: Asia-Pacific: Cardiology Pet Market, By Country, 2010 - 2017 ($Million)
  • Table 43: Asia-Pacific: Neurology Pet Market, By Country, 2010 - 2017 ($Million)
  • Table 44: Asia-Pacific: Other Pet Applications Market, By Country, 2010 - 2017 ($Million)
  • Table 45: Asia-Pacific: Radiopharmaceutical Therapeutic Application Market, 2010 - 2017 ($Million)
  • Table 46: Asia-Pacific: Radiopharmaceutical Therapeutic Application Market, By Country, 2010 - 2017 ($Million)
  • Table 47: Asia-Pacific: Radiopharmaceutical Thyroid Application Market, By Country, 2010 - 2017 ($Million)
  • Table 48: Asia-Pacific: Radiopharmaceutical Bone Metastasis Application Market, By Country, 2010 - 2017 ($Million)
  • Table 49: Asia-Pacific: Radiopharmaceutical Lymphoma Application Market, By Country, 2010 - 2017 ($Million)
  • Table 50: Asia-Pacific: Radiopharmaceutical Endocrine Application Market, By Country, 2010 - 2017 ($Million)
  • Table 51: Asia-Pacific: Radiopharmaceutical Other Applications Market, By Country, 2010 - 2017 ($Million)
  • Table 52: Asia-Pacific: Stable Isotope Market, 2010 - 2017 ($Million)
  • Table 53: Asia-Pacific: Stable Isotope Market, By Country, 2010 - 2017 ($Million)
  • Table 54: Asia-Pacific: Carbon Stable Isotope Market, By Country, 2010 - 2017 ($Million)
  • Table 55: Asia-Pacific: Deuterium Stable Isotope Market, By Country, 2010 - 2017 ($Million)
  • Table 56: Asia-Pacific: Oxygen Stable Isotope Market, By Country, 2010 - 2017 ($Million)
  • Table 57: Asia-Pacific: Nitrogen Stable Isotope Market, By Country, 2010 - 2017 ($Million)
  • Table 58: Asia-Pacific: Other Stable Isotope Market, By Country, 2010 - 2017 ($Million)
  • Table 59: Asia-Pacific: Enriched Stable Isotope Market, By Application, 2010 - 2017 ($Million)
  • Table 60: Asia-Pacific: Stable Isotopes Market For Diagnostic & Therapeutic Applications, By Country, 2010 - 2017 ($Million)
  • Table 61: Asia-Pacific: Stable Isotopes Market For Research Applications, By Country, 2010 - 2017 ($Million)
  • Table 62: Asia-Pacific: Stable Isotopes Market For Pharmaceutical Applications, By Country, 2010 - 2017 ($Million)
  • Table 63: Asia-Pacific: Stable Isotopes Market For Industrial Applications, By Country, 2010 - 2017 ($Million)
  • Table 64: Asia-Pacific: Radiopharmaceuticals Market, By Country, 2010 - 2017 ($Million)
  • Table 65: Japan: Spect Radiopharmaceutical Market, 2010 - 2017 ($Million)
  • Table 66: Japan: Pet Radiopharmaceutical Market, 2010 - 2017 ($Million)
  • Table 67: Japan: Radiopharmaceutical Market, By Therapy, 2010 - 2017 ($Million)
  • Table 68: Japan: Beta Emitter Market, By Isotope, 2010 - 2017 ($Million)
  • Table 69: Japan: Brachytherapy Market, By Isotope, 2010 - 2017 ($Million)
  • Table 70: Japan: Stable Isotope Market, 2010 - 2017 ($Million)
  • Table 71: China: Spect Radiopharmaceutical Market, 2010 - 2017 ($Million)
  • Table 72: China: Pet Radiopharmaceutical Market, 2010 - 2017 ($Million)
  • Table 73: China: Radiopharmaceutical Market, By Therapy, 2010 - 2017 ($Million)
  • Table 74: China: Beta Emitter Market, By Isotope, 2010 - 2017 ($Million)
  • Table 75: China: Brachytherapy Market, By Isotope, 2010 - 2017 ($Million)
  • Table 76: China: Stable Isotope Market, 2010 - 2017 ($Million)
  • Table 77: India: Spect Radiopharmaceutical Market, 2010 - 2017 ($Million)
  • Table 78: India: Pet Radiopharmaceutical Market, 2010 - 2017 ($Million)
  • Table 79: India: Radiopharmaceutical Market, By Therapy, 2010 - 2017 ($Million)
  • Table 80: India: Beta Emitter Market, By Isotope, 2010 - 2017 ($Million)
  • Table 81: India: Brachytherapy Market, By Isotope, 2010 - 2017 ($Million)
  • Table 82: India: Stable Isotope Market, 2010 - 2017 ($Million)
  • Table 83: S. Korea: Spect Radiopharmaceutical Market, 2010 - 2017 ($Million)
  • Table 84: S. Korea: Pet Radiopharmaceutical Market, 2010 - 2017 ($Million)
  • Table 85: S. Korea: Radiopharmaceutical Market, By Therapy, 2010 - 2017 ($Million)
  • Table 86: S. Korea: Beta Emitter Market, By Isotope, 2010 - 2017 ($Million)
  • Table 87: S. Korea: Brachytherapy Market, By Isotope, 2010 - 2017 ($Million)
  • Table 88: S. Korea: Stable Isotope Market, 2010 - 2017 ($Million)
  • Table 89: Malaysia: Spect Radiopharmaceutical Market, 2010 - 2017 ($Million)
  • Table 90: Malaysia: Pet Radiopharmaceutical Market, 2010 - 2017 ($Million)
  • Table 91: Malaysia: Radiopharmaceutical Market, By Therapy, 2010 - 2017 ($Million)
  • Table 92: Malaysia: Beta Emitter Market, By Isotope, 2010 - 2017 ($Million)
  • Table 93: Malaysia: Brachytherapy Market, By Isotope, 2010 - 2017 ($Million)
  • Table 94: Malaysia: Stable Isotope Market, 2010 - 2017 ($Million)
  • Table 95: Indonesia: Spect Radiopharmaceutical Market, 2010 - 2017 ($Million)
  • Table 96: Indonesia: Pet Radiopharmaceutical Market, 2010 - 2017 ($Million)
  • Table 97: Indonesia: Radiopharmaceutical Market, By Therapy, 2010 - 2017 ($Million)
  • Table 98: Indonesia: Beta Emitter Market, By Isotope, 2010 - 2017 ($Million)
  • Table 99: Indonesia: Brachytherapy Market, By Isotope, 2010 - 2017 ($Million)
  • Table 100: Indonesia: Stable Isotope Market, 2010 - 2017 ($Million)
  • Table 101: Australia: Spect Radiopharmaceutical Market, 2010 - 2017 ($Million)
  • Table 102: Australia: Pet Radiopharmaceutical Market, 2010 - 2017 ($Million)
  • Table 103: Australia: Radiopharmaceutical Market, By Therapy, 2010 - 2017 ($Million)
  • Table 104: Australia: Beta Emitter Market, By Isotope, 2010 - 2017 ($Million)
  • Table 105: Australia: Brachytherapy Market, By Isotope, 2010 - 2017 ($Million)
  • Table 106: Australia: Stable Isotope Market, 2010 - 2017 ($Million)
  • Table 107: New Zealand: Spect Radiopharmaceutical Market, 2010 - 2017 ($Million)
  • Table 108: New Zealand: Pet Radiopharmaceutical Market, 2010 - 2017 ($Million)
  • Table 109: New Zealand: Radiopharmaceutical Market, By Therapy, 2010 - 2017 ($Million)
  • Table 110: New Zealand: Beta Emitter Market, By Isotope, 2010 - 2017 ($Million)
  • Table 111: New Zealand: Brachytherapy Market, By Isotope, 2010 - 2017 ($Million)
  • Table 112: New Zealand: Stable Isotope Market, 2010 - 2017 ($Million)
  • Table 113: Roa: Spect Radiopharmaceutical Market, 2010 - 2017 ($Million)
  • Table 114: Roa: Pet Radiopharmaceutical Market, 2010 - 2017 ($Million)
  • Table 115: Roa: Radiopharmaceutical Market, By Therapy, 2010 - 2017 ($Million)
  • Table 116: Roa: Beta Emitter Market, By Isotope, 2010 - 2017 ($Million)
  • Table 117: Roa: Brachytherapy Market, By Isotope, 2010 - 2017 ($Million)
  • Table 118: Roa: Stable Isotope Market, 2010 - 2017 ($Million) 221
  • Table 119: Agreements, Partnerships, Collaborations & Joint Ventures, 2010 - 2013
  • Table 120: Products Launch, 2010 - 2013
  • Table 121: Expansions, 2010 - 2012
  • Table 122: Mergers & Acquisitions, 2010 - 2012
  • Table 123: Other Developments, 2010 - 2012
  • Table 124: Cambridge Isotope Laboratories Inc.: Total Revenue, By Segment, 2010 - 2012 ($Million)
  • Table 125: Cambridge Isotope Laboratories Inc.: Total Revenue, By Geography, 2010 - 2012 ($Million)
  • Table 126: Cardinal Health, Inc.: Total Revenue, By Segment, 2010 - 2012 ($Million)
  • Table 127: Cardinal Health, Inc.: Total Revenue, By Geography, 2010 - 2012 ($Million)
  • Table 128: Covidien, Plc: Total Revenue And R&D Expenditure, 2010 - 2012 ($Million)
  • Table 129: Covidien, Plc: Total Revenue, By Segment, 2010 - 2012 ($Million)
  • Table 130: Covidien, Plc: Total Revenue, By Geography, 2010 - 2012 ($Million)
  • Table 131: Fujifilm Holdings Corp: Total Revenue, By Segment, 2010 - 2012 ($Million)
  • Table 132: Fujifilm Holdings Corp: Total Revenue, By Geography, 2010 - 2012 ($Million)
  • Table 133: General Electric Company: Total Revenue And R&D Expenses, 2009 - 2011 ($Billion)
  • Table 134: General Electric Company: Total Revenue, By Segment, 2009 - 2011 ($Billion)
  • Table 135: General Electric Company: Total Revenue, By Geography, 2009 - 2011 ($Billion)
  • Table 136: Iba Group: Market Revenue, By Segment, 2009 - 2011 ($Million)
  • Table 137: Iba Group: Total Revenue, By Geography, 2009 - 2011 ($Million)
  • Table 138: Isotec Inc.: Total Revenue, By Segment, 2009 - 2011 ($Million)
  • Table 139: Isotec Inc.: Total Revenue, By Geography, 2009 - 2011 ($Million)
  • Table 140: Lantheus: Total Revenue, By Segment, 2009 - 2011 ($Million)
  • Table 141: Lantheus: Total Revenue, By Geography, 2009 - 2011 ($Million)
  • Table 142: Nordion, Inc.: Total Revenue, By Segment, 2010 - 2012 ($Million)
  • Table 143: Siemens Ag: Total Revenue And R&D Expenses, 2010 - 2012 ($Million)
  • Table 144: Siemens Ag: Total Revenue, By Segment, 2010 - 2012 ($Million)
  • Table 145: Siemens Ag: Total Revenue, By Geography, 2010 - 2012 ($Million)
  • Table 146: Taiyo Nippon Sanso, Corp.: Total Revenue, By Geography, 2010 - 2012 ($Million)

List Of Figures

  • Figure 1: Asia-Pacific: Radiopharmaceuticals Market, By Segment, 2010 - 2017
  • Figure 2: Asia-Pacific: Radiopharmaceuticals Market, By Country, 2012
  • Figure 3: Asia-Pacific: Stable Isotopes Market, 2012 - 2017 ($Million)
  • Figure 4: Radiopharmaceuticals Market Segmentation
  • Figure 5: Enriched Stable Isotopes Market Segmentation
  • Figure 6: Market Dynamics
  • Figure 7: Asia-Pacific: Radiopharmaceuticals Market Share Analysis, By Key Players, 2012
  • Figure 8: Asia-Pacific: Enriched Stable Isotope Market Share Analysis, By Key Players, 2012
  • Figure 9: Opportunity Matrix: Asia-Pacific Diagnostic Radiopharmaceuticals Market, 2012
  • Figure 10: Spect Radiopharmaceuticals Market Share, 2012
  • Figure 11: Pet Radiopharmaceuticals Market Share, 2012
  • Figure 12: Opportunity Matrix: Asia-Pacific Therapeutic Radiopharmaceuticals Market, 2012
  • Figure 13: Ra-223 Decay Chain
  • Figure 14: Porter's Five Forces Analysis For Alpharadin
  • Figure 15: Swot Analysis Of Alpharadin
  • Figure 16: Asia-Pacific: Diagnostic Radiopharmaceuticals Market, By Indication, 2012
  • Figure 17: Key Growth Strategies, 2010 - 2013
  • Figure 18: Cambridge Isotope Laboratories, Inc.: Total Revenue And R&D Expenses, 2010 - 2012 ($Billion)
  • Figure 19: Cardinal Health, Inc.: Total Revenue, 2010 - 2012 ($Billion)
  • Figure 20: Covidien, Plc: Radiopharmaceuticals Revenue, 2010 - 2012 ($Billion)
  • Figure 21: Fujifilm Holdings Corp: Total Revenue And R&D Expenditure, 2010 - 2012 ($Billion)
  • Figure 22: Iba Group: Total Market Revenue, 2009 - 2011 ($Million)
  • Figure 23: Isotec Inc.: Total Revenue And R&D Expenses, 2009 - 2011 ($Billion)
  • Figure 24: Lantheus: Total Revenue And R&D Expenses, 2009 - 2011 ($Million)
  • Figure 25: Nordion, Inc.: Total Market Revenue, 2010 - 2012 ($Billion)
  • Figure 26: Taiyo Nippon Sanso, Corp.: Total Revenue And R&D Expenditure, 2010 - 2012 ($Billion)
  • Figure 27: Urenco Limited: Total Market Revenue, 2009 - 2011 ($Billion)
Back to Top